US92686J1060 - Common Stock
VIKING THERAPEUTICS INC
NASDAQ:VKTX (5/1/2024, 7:00:03 PM)
After market: 76.69 +0.26 (+0.34%)76.43
-3.15 (-3.96%)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 23 full-time employees. The company went IPO on 2015-04-29. The firm's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRb). The firm is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The company is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The company is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. The Company’s other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA 92130
P: 18587044660
CEO: Brian Lian
Employees: 23
Website: https://vikingtherapeutics.com/
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
This midcap biotech could see huge success ahead -- or disappointment.
Tom Lee of Fundstrat Global Advisors thinks the small-cap Russell 2000 could climb 50% by the end of 2024.
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip.
Here you can normally see the latest stock twits on VKTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: